Eli Lilly's Trulicity nabs novel CV approval in patients with or without established disease
Eli Lilly's Trulicity is in a heated battle with Novo's Ozempic for supremacy in the GLP-1 market. (Eli Lilly)
Analysts and investors were less than amazed when Eli Lilly revealed cardiovascular outcomes data for its GLP-1 diabetes med Trulicity in late 2018. It wasn't that the study didn't hit its mark, they argued, but that the results weren't impressive enough to move the needle in a competitive field.
But the data was impressive enough to score Trulicity a first-of-its-kind approval from the FDA, potentially putting analysts' worries to rest.
The FDA on Friday approved Trulicity to reduce the risk of cardiovascular events in Type 2 diabetes patients with—or without—established CV disease, Lilly said in a release.
Watch the Free Webinar
Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production
Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.
The approval marks a win for Lilly after results from Trulicity's Rewind CV outcomes trial failed to win over skeptical analysts when top-line results came out in November 2018.